OPK Biotech Develops Research and Production in Russia
OPK Biotech disposes of certificated production facilities, with the capacity to manufacture about 100 thousand doses (250ml) of Hemopure, 347 thousand doses of Oxyglobin (125 ml), or 647 thousand doses of Oxyglobin (60 ml) a year. The company also has all estimated and technical documents required for the construction of factories, able to produce more than 500 thousand doses of Hemopure a year.
OPK Biotech aims at expanding scientific explorations, increasing the production base by means of new high-technological productions in different regions in the world, as well as developing global marketing to promote their high-technological products.
In particular, OPK Biotech and OPK plans imply the development of research-and-production complex in Russia, as well as further perfectionning of these technologies with the participation of Russian scientists and specialists.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.